A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Launched by PFIZER · Jan 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a medication called Abrocitinib to see how safe and effective it is for adults with moderate to severe atopic dermatitis, also known as eczema. Atopic dermatitis is a long-term skin condition that causes inflammation, redness, and irritation. The study is open to adults over 18 years old who have been diagnosed with this condition and meet certain health criteria. Participants should not have any medical issues that would prevent them from safely taking Abrocitinib.

If you decide to join the study, you will take Abrocitinib in tablet form once a day for two years and can also use prescribed creams for your skin. Throughout the study, you will visit the clinic about five times, roughly once every four to six months. This will help researchers understand how well the medication works and if it is safe for people with atopic dermatitis. Your participation could contribute to important insights about this treatment for others with the same condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years of age at inclusion.
• • Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
• • Patients that have been informed of the study procedures and have signed the consent.
• Exclusion Criteria:
• • Patients for whom abrocitinib is contraindicated.
• • Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
• • Patients not affiliated to the French social security system.
• • Patients deprived of liberty, under guardianship, or unable to provide oral consent.
• • Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).